FY2020 · ended Dec 31, 2020 · Revenue $7.87M, -65.0% YoY · Filed Mar 15, 2022
Cogent Biosciences, Inc. (COGT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$266.0 million. As of Jun 30, 2026 it held $792.3 million in cash and investments and $244.3 million in total debt.
Revenue
$7.87M
-65.0% vs prior year
Net income
$-328.94M
-28.6% vs prior year
Operating cash flow (TTM)
$-307.55M
-31.6% vs year-ago TTM
Free cash flow (TTM)
$-309.24M
-31.8% vs year-ago TTM
EPS
$-2.16
-11.3% vs prior year
Dividend per share
None
Shares outstanding
162.31M
+42.6% vs prior year
Net cash
$548.04M
as of Jun 30, 2026
Operating margin
-1044.3%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COGT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1622229
- Former names
- Unum Therapeutics Inc. (until Oct 5, 2020); Unum Therapeutics, Inc. (until Mar 30, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$333.4M | -$275.9M | -$208.1M | -$147.8M | -$75.6M |
| Net income | -$328.9M | -$255.9M | -$192.4M | -$140.2M | -$72.3M |
| Diluted EPS | -$2.16 | -$1.94 | -$1.94 | -$1.73 | — |
| Operating cash flow | -$264.4M | -$207.8M | -$153.6M | -$118.6M | -$58.8M |
| Free cash flow | -$266.0M | -$208.4M | -$156.4M | -$125.5M | -$60.5M |
| Total assets | $937.6M | $327.9M | $313.4M | $300.8M | $232.1M |
| Total liabilities | $301.2M | $71.6M | $55.6M | $45.1M | $17.9M |
| Stockholders' equity | $636.4M | $256.3M | $257.8M | $255.7M | $214.2M |
| Cash and investments | $900.8M | $287.1M | $273.2M | $259.3M | $219.7M |
| Total debt | $238.8M | $17.5M | $18.9M | $19.6M | $3.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 2, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
All 614 Cogent Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.